Clinical studies presented at the American Heart Association 2022 Scientific Sessions event demonstrate compelling diagnostic and health economic value of the Zio suite of products across a range of clinical applications
A new analysis of iRhythm’s mSToPS trial, presented at the American Heart Association, reveals that Zio XT provided high value from a health economic perspective
SAN FRANCISCO, Nov. 06, 2022 iRhythm Technologies, Inc. , a leading cardiovascular diagnostics and digital healthcare solutions company focused on creating trusted solutions that detect,. | November 6, 2022
New Research Confirms that Zio® by iRhythm Provides High Value From a Health Economic Perspective streetinsider.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from streetinsider.com Daily Mail and Mail on Sunday newspapers.